Reversal of cognitive decline with multitherapy (not monotherapy)

Created December 2016

Reversal of cognitive decline: A novel therapeutic program

Aging: Volume 6, Issue 9 pp 707—717 10.18632/aging.100690

Dale E. Bredesen 1, 2

1 Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, University of California, Los Angeles, CA 90095;

2 Buck Institute for Research on Aging, Novato, CA 94945

Vitamin D is just one of many therapies he used to reverse cognitive declineI have long thought that multiptherpy would be better than monotherapyMany of the diseases which vitamin D has been proven to treat are also treated by Magnesium (which also increases Vitamin D) Vitamin K2 (this study), Omega-3 (which also increases Vitamin D) Boron (which also increases Vitamin D) Posit (this study), Resveratrol ( (which also increases Vitamin D, this study) Zinc (essential for Vitamin D, this study)See also Vitamin D Life* Omega-3 etc improved both cognition and mobility of older women – Aug 2015* Cognitive decline in elderly slowed by Omega-3 – meta-analysis May 2015* Cognition of Alzheimer’s patients improved by daily 4,000 IU of vitamin D – RCT Jan 2015* Low vitamin D with metabolic syndrome increased risk of senior cognitive impairment by 3X – July 2016* Paper on current page reduces Metabolic Syndrome in many ways* Vitamin K and cognition in the elderly* Alzheimer’s and Vitamins D, B, C, E, as well as Omega-3, metals, etc. – June 2013* Metals include Selenium, Zinc, Iron, and Copper* Dementia less likely with increased levels of Magnesium etc.* Posit Science - greatly increases memory* Decrease of Alzheimer’s biomarker halted by Resveratrol (perhaps due to vitamin D) – RCT Sept 2015* Vitamin D Cofactors in a nutshell - includes Mg, Vit K, Omega-3, boron, Zinc, * Overview Parkinson's and Vitamin DOverview Alzheimer's-Cognition and Vitamin D starts with the following summary {include} 1. Subsequent papers by the same author* Inhalational Alzheimer's disease: an unrecognized - and treatable - epidemic - Feb 2016 * 📄 Download the PDF from Vitamin D Life* Reversal of cognitive decline in Alzheimer's disease - June 2016 * "Here I report that type 3 Alzheimer’s disease is a phenotypic manifestation of CIRS." (chronic inflammatory response syndrome)* 📄 Download the PDF from Vitamin D Life

📄 Download the PDF from Vitamin D Life

This report describes a novel, comprehensive, and personalized therapeutic program that is based on the underlying pathogenesis of Alzheimer's disease, and which involves multiple modalities designed to achieve metabolic enhancement for neurodegeneration (MEND).

The first 10 patients who have utilized this program include patients with memory loss associated with

Alzheimer's disease (AD), a
mnestic mild cognitive impairment (aMCI), or
subjective cognitive impairment (SCI).

Nine of the 10 displayed subjective or objective improvement in cognition beginning within 3-6 months , with the one failure being a patient with very late stage AD.

Six of the patients had had to discontinue working or were struggling with their jobs at the time of presentation, and all were able to return to work or continue working with improved performance.

Improvements have been sustained, and at this time the longest patient follow-up is two and one-half years from initial treatment, with sustained and marked improvement.

These results suggest that a larger, more extensive trial of this therapeutic program is warranted.

The results also suggest that, at least early in the course, cognitive decline may be driven in large part by metabolic processes .

Furthermore, given the failure of monotherapeutics in AD to date, the results raise the possibility that such a therapeutic system may be useful as a platform on which drugs that would fail as monotherapeutics may succeed as key components of a therapeutic system.

Tags: Cognitive